SEARCH

SEARCH BY CITATION

References

  • 1
    Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 33552.
  • 2
    Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009; 29: 1007.
  • 3
    Lau GK, Piratvisuth T et al., for the Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group, Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 268295.
  • 4
    Van Zonneveld M, Zondervan PE et al., for the HBV 99-01 Study Group. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int 2006; 26: 399405.
  • 5
    Chang TT, Gish RG et al., for the BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 100110.
  • 6
    Lai CL, Gane E, et al., for the GLOBE Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 257688.
  • 7
    Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 244255.
  • 8
    Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 15227.
  • 9
    Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116: 82934.
  • 10
    Hui CK, Leung N, Shek TW, et al. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology 2007; 46: 6908.
  • 11
    Yang HI, Lu SN et al., for the Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 16874.
  • 12
    Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45: 118792.
  • 13
    Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 50739.
  • 14
    Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 26383.
  • 15
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 22742.
  • 16
    Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997; 26: 133842.
  • 17
    Di Bisceglie AM, Waggoner JG, Hoofnagle JH. Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers: correlation with serum markers and changes associated with loss of hepatitis B e antigen after antiviral therapy. Gastroenterology 1987; 93: 123641.
  • 18
    Van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52: 4204.
  • 19
    Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47: 42834.
  • 20
    Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 143744.
  • 21
    Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 48695.
  • 22
    Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 4552.
  • 23
    Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 9715.
  • 24
    Van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39: 80410.
  • 25
    Ni YH, Chang MH, Chen PJ, et al. Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion. Gastroenterology 2007; 132: 23405.
  • 26
    Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat 2007; 14: 14752.
  • 27
    Liu CJ, Chen PJ, Lai MY, et al. Viral factors correlate with hepatitis B e antigen seroconversion in patients with chronic hepatitis B. Liver Int 2006; 26: 94955.
  • 28
    Chu CM, Liaw YF. Spontaneous relapse of hepatitis in inactive HBsAg carriers. Hepatol Int 2007; 1: 3115.
  • 29
    Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 14227.
  • 30
    Ahn SH, Park YN, Park JY, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005; 42: 18894.
  • 31
    Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006; 119: e916.
  • 32
    Yuen MF, Wong DK, Yuan HJ, Sum SM, Lai CL. HBsAg seroclearance in Chinese patients receiving lamivudine therapy for chronic hepatitis B virus infection. J Clin Microbiol 2004; 42: 48824.
  • 33
    Coffin CS, Lee SS. Treatment of HbeAg-positive patients with nucleos/tide analogues. Liver Int 2009; 29: 11624.
  • 34
    Janssen HL, Van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 1239.
  • 35
    Lau GK, Piratvisuth T, Thongsawat S, et al. Durability of response to peginterferon alfa-2a (40 KD) (PEGASYS®) in Asian patients with HBeAg-positive chronic hepatitis B: 12 month follow-up data from a large, randomized study (abstract no. 49). Presented at the 2006 Shanghai-Hong Kong International Liver Congress, 25–28 March 2006, Shanghai, China.
  • 36
    Piratvisuth T, Lau G, Chao YC, et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int 2008; 2: 10210.
  • 37
    Janssen HLA. Peg-interferon for chronic hepatitis B. Presented at the 13th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD), 20–24 May 2009, Washington, DC.
  • 38
    Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49: 63451.
  • 39
    Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10: 298305.
  • 40
    Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54: 100913.
  • 41
    Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 9981002.
  • 42
    Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002; 36: 142530.
  • 43
    Zhao H, Kurbanov F, Wan MB, et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis 2007; 44: 5418.
  • 44
    Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008; 47: 44754.
  • 45
    Marcellin P, Chang TT et al., for the Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 80816.
  • 46
    Ren FY, Piao DM, Piao XX. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol 2007; 13: 42647.
  • 47
    Yao GB, Zhu M, Wang YM, et al. A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B [Chinese]. Zhonghua Nei Ke Za Zhi 2006; 45: 8915.
  • 48
    Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009; 49: 729.
  • 49
    Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 125663.
  • 50
    Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147: 74554.
  • 51
    Yao G, Chen C-W, Lu W-L, et al. Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol Int 2008; 2: 48693.
  • 52
    Leung NW, Peng CY, Sollano J, et al. Entecavir (ETV) results in higher HBV DNA reduction versus adefovir (ADV) in antiviral-naïve HBeAg(+) adults with high HBV DNA: week 96 results (E.A.R.L.Y Study) (abstract no. 998). J Hepatol 2008; 48 (Suppl.): S3734.
  • 53
    Yao GB, Xu DZ, Ren H, et al. Three years of continuous treatment with entecavir results in high proportions of Chinese nucleoside-naïve patients with undetectable HBV DNA: results from studies ETV-023 and -050 (abstract no. 714). J Hepatol 2008; 48 (Suppl.): S2667.
  • 54
    Chang TT, Yoonn SK, Lai CL, et al. Five year of continuous entecavir (ETV) for nucleoside naive HbeAg (+) chronic hepatitis B (CHB): results from study ETV-901 (abstract no. PE115). Hepatol Int 2009; 3 (Suppl.): 86.
  • 55
    Heathcote JE, Gane E, DeMan R, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103) (abstract no. 158). Hepatology 2008; 48 (Suppl.): 376A.
  • 56
    Heathcote EJ, Gane E, DeMan RA, et al. Three years of tenofovir disoproxil (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (study 103): preliminary analysis (abstract no. 483). Hepatology 2009; 50 (Suppl.): 533A.
  • 57
    Zeuzem S, Gane E, Liaw YK, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51: 1120.
  • 58
    Hou J, Jia J, Yin YK, et al. Phase III comparative trial of telbivudine vs lamivudine in Chinese patients: two-year results. Hepatol Int 2007; 1: 13.
  • 59
    Jia JD, Hou JL, Yin YK, et al. Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in Chinese chronic hepatitis B. Hepatol Int 2009; 3: 43.
  • 60
    Evans A, Riva A, Cooksley H, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 2008; 48: 75969.
  • 61
    Wu Z, Yan W, Guo W, et al. Telbivudine preserves Th1 cytokine and inhibits Th2 cytokine production in MHV-3 induced viral hepatitis model (abstract no. 945). Hepatology 2008; 48 (Suppl.): 731A.
  • 62
    Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer Semin Immunopathol 1995; 17: 26181.
  • 63
    Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5: 21529.
  • 64
    Peng G, Li S, Wu W, et al. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 2008; 45: 96370.
  • 65
    Lau GKK. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? Liver Int 2009; 29: 1259.
  • 66
    Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92: 183943.
  • 67
    Liaw YF, Leung NWY et al., for the Asian Hepatitis Lamivudine Study Group. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 17280.
  • 68
    Yuan HJ, Ka-Ho Wong D, Doutreloigne J, et al. Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B. J Infect 2007; 54: 497503.
  • 69
    Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000; 15 (Suppl.): E2530.
  • 70
    Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 8036.
  • 71
    Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37: 74855.
  • 72
    Lee HC, Suh DJ, Ryu SH, et al. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Gut 2003; 52: 177983.
  • 73
    Lee KM, Cho SW, Kim SW, et al. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002; 9: 20812.
  • 74
    Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38: 126773.
  • 75
    Poynard T, Hou JL, Chutaputti A, Manns M, Naoumov N. Sustained durability of HBeAg seroconversion in chronic hepatitis B patients after treatment with telbivudine (abstract no. 706). J Hepatol 2008; 48 (Suppl.): S2634.